Drug Research
Antisense oligomer AVI-4126 has bioavailability in malignant tumors
Published in Gene Therapy Weekly, July 14th, 2005
According to recent research published in the journal Clinical Cancer Research, "phosphorodiamidate morpholino oligomers (PIVIO) inhibit targeted gene expression by preventing ribosomal assembly, thereby preventing mRNA translation. AVI-4126, a PIVIO targeted against c-MYC, has been extensively characterized in multiple cancer and other disease models and is currently in human clinical trials."
"A phase I clinical study was conducted to address the issue of PMO bioavailability in malignant tumors surgically excised from patients with adenocarcinoma of prostate and breast 1...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2005-07-14)
More Articles from Gene Therapy Weekly
- Brain Cancer
Interleukin-2 gene delivery sends glioblastoma into remission in rats - Neurology
Angiogenic gene therapy diminishes cisplatin-induced peripheral neuropathy - Spinal Cord Injury
Poliovirus replicons encoding interleukin-10 encourage spinal cord recovery - Urology
Promyelocytic leukemia cDNA stifles bladder cancer cell growth - Allergy and Immunology
Heat shock protein 70 propels gene-directed enzyme prodrug therapy - Amyotrophic Lateral Sclerosis
Motor neuron disease examined, role of truncated SOD1 clarified - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
